Share price of Aurobindo Pharma rises as Nifty weakens

Share price of Aurobindo Pharma rises as Nifty weakens
ETMarkets.com
Rate Story
Share
Font Size
Save
Comment
Synopsis

A total of 81,443 shares changed hands on the counter till 01:09PM (IST).

Getty Images
Nagaraj Shetti, Technical Research Analyst at HDFC Securities, believes Monday's pattern could be considered as a High Wave, which reflects high volatility in the market at swing highs.
Shares of . gained 0.09 per cent to Rs 447.3 in Friday's trade as of 01:09PM (IST).

The stock hit a high price of Rs 447.8 and low of Rs 439.45 during the session.

The return on equity (ROE) for the stock stood at 10.77 per cent. Traded volume on the counter stood at 01:09PM shares and turnover at Rs 3.6 crore around that time.

The stock of Aurobindo Pharma Ltd. quoted a 52-week high and 52-week low prices of Rs 742.25 and Rs 439.45, respectively.

The Beta value of the counter, which measures its volatility in relation to the broader market, stood at 1.06.

Promotor/FII Holding
Promoters held 51.83 per cent stake in the company as of 30-Sep-2022, while foreign investors held 22.43 per cent and domestic institutional investors had 16.55 per cent.

Key Financials
The company reported consolidated sales of Rs 5796.56 crore for the quarter ended 30-Sep-2022, down 7.65 per cent from previous quarter's Rs 6276.54 crore and down 4.01 per cent from the year-ago quarter's Rs 6038.5 crore.

Net profit after tax for the latest quarter stood at Rs 409.45 crore, down 41.25 per cent from the same quarter a year ago.
Experience Your Economic Times Newspaper, The Digital Way!

Read More News on

(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)

Download The Economic Times News App to get Daily Market Updates & Live Business News.

...more
Pick the best stocks for yourself
Powered by
Read before you invest. Insights on Aurobindo Pharma Ltd.. Explore Now